CCORF Maintains Atara Biotherapeutics(ATRA.US) With Buy Rating, Raises Target Price to $21
Canaccord Genuity Maintains Buy on Atara Biotherapeutics, Raises Price Target to $21
Atara Biotherapeutics Analyst Ratings
Atara Biotherapeutics: Hold Rating Maintained Amid Financial Shortfalls and Regulatory Uncertainties
H.C. Wainwright Maintains Atara Biotherapeutics(ATRA.US) With Hold Rating
Atara Biotherapeutics (ATRA) Gets a Hold From Stifel Nicolaus
Atara Biotherapeutics Analyst Ratings
Mizuho Securities Upgrades Atara Biotherapeutics(ATRA.US) to Buy Rating, Cuts Target Price to $18
CCORF Maintains Atara Biotherapeutics(ATRA.US) With Buy Rating, Maintains Target Price $13
Atara Biotherapeutics Analyst Ratings
Canaccord Genuity Maintains Buy on Atara Biotherapeutics, Maintains $13 Price Target
CCORF Maintains Atara Biotherapeutics(ATRA.US) With Buy Rating, Maintains Target Price $13
Atara Biotherapeutics Receives Buy Rating Amidst Positive FDA Review and Solid Financial Outlook
Atara Biotherapeutics Analyst Ratings
Atara Biotherapeutics Hold Rating Based on Promising Preclinical Data and Awaited Clinical Trials
Stifel Nicolaus Sticks to Its Hold Rating for Atara Biotherapeutics (ATRA)
HC Wainwright & Co. : Reiterates Atara Biotherapeutics' (ATRA.US) neutral rating.
Atara Biotherapeutics Analyst Ratings
Atara Biotherapeutics: A Balanced Hold Amidst FDA Approval Prospects and Valuation Uncertainties
Analysts Have Conflicting Sentiments on These Healthcare Companies: Deciphera Pharmaceuticals (DCPH), Atara Biotherapeutics (ATRA) and Nkarta (NKTX)